Antibody titre – Page 5 – Communicable Diseases Research

Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)

SARS-COV-2에 대한 예방 접종 전 항체 반응의 결정 인자 : 인구 기반 종단 연구 (Covidence UK)

Research Article

Published on 2022-02-222022-09-01
Journal: BMC Medicine [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단,

Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany

독일 성인 인구의 체액성 SARS-CoV-2 백신 반응의 비교 규모 및 지속성

Multicenter Study

Published on 2022-02-162022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] ACE2 binding analyzed antibodies antibody antibody persistence Antibody Response Antibody titre antibody titres booster Comparative concerning dose Efficacy explain focus Germany healthcare Healthcare workers heterologous prime-boost homologous immune protection immune response immune responses immunocompromised individual immunocompromised individuals increases in infected individual information longitudinal study mRNA vaccination mRNA vaccines mRNA-based Neutralizing peaked Population population-based study produced proportion protective immunity question RBD recent recipient recipients reduced response robust SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 infections second vaccination significantly higher specific antibodies subpopulation subpopulations titre triggered vaccination Vaccine vaccine-induced immune response vaccine-induced immune responses variants variants of concern vector-based vaccines while wild-type
[DOI] 10.3389/fimmu.2022.828053 PMC 바로가기 [Article Type] Multicenter Study

The Effect of Smoking on Humoral Response to COVID-19 Vaccines: A Systematic Review of Epidemiological Studies

Review

Published on 2022-02-162022-10-28
Journal: Vaccines [Category] COVID-19,

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Randomized Controlled Trial

Published on 2022-02-102022-10-04
Journal: The European Respiratory Journal [Category] COVID19(2023년), SARS, 임상,

[키워드] 1:1 28-day mortality 95% CI age Antibody titre assigned baseline Clinical improvement clinical trial convalescent plasma coronavirus disease COVID-19 Critically ill days alive Effect enrolment group groups hospitalised hospitalised patient interquartile range invasive investigator-initiated IQR Laboratory male marker median no significant difference Open-label Parallel Arm Patient patients plasma Primary outcome proportion randomisation randomised Randomly Respiratory Support Secondary outcomes Standard of care subgroups symptom onset the median therapy Trial ventilatory support with COVID-19
[DOI] 10.1183/13993003.01471-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial

Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study

Research article

Published on 2022-02-012022-10-05
Journal: The Lancet Regional Health - Europe [Category] 유전자 메커니즘,

[키워드] addition administration age anti-S anti-S antibody Anti-spike antibody Antibody titre Antiretroviral therapy ART CD4+ T cell Cell Cohort cohort study collected Combination COVID-19 COVID-19 emergency detectable enrolled finding funding HIV HIV infection humoral immune response individual Italian male median Ministry of Health mRNA-1273 mRNA-1273 vaccine neutralising antibody activity not affected Outpatient performed plasma PLWHIV powerful tool Primary outcome produced prospective cohort robust SARS-CoV-2 SARS-CoV-2 pandemic sera stratified supported titre two-dose regimen vaccination vaccination schedule Viral load with COVID-19 with HIV
[DOI] 10.1016/j.lanepe.2021.100287 [Article Type] Research article

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

인도 의료 종사자들 사이에서 ChAdOx1-nCOV(Covishield™) 및 BBV-152(Covaxin™) 백신을 사용한 체액 항체 동역학: 6개월 종단면 코로나바이러스 백신 유도 항체 역가(COVAT) 연구

Article

Published on 2022-02-012022-09-12
Journal: Diabetes & metabolic syndrome [Category] COVID19(2023년), MERS, SARS, 진단,

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies

흡연이 COVID-19 백신에 대한 면역학적 반응에 영향을 미칩니까? VASCO 연구의 증거 및 추가 연구의 필요성

Article

Published on 2022-02-012022-09-12
Journal: Public health [Category] COVID19(2023년), MERS, SARS, 진단,

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Research

Published on 2022-01-242022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19, SARS,

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

BNT162b2 COVID-19 백신 수혜자의 점막 면역 반응

Clinical Trial

Published on 2022-01-012022-09-12
Journal: EBioMedicine [Category] 임상, 진단,

[키워드] acquisition activated Antibody titre baseline BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine collected Concentration COVID-19 COVID-19 vaccine Department elicit ELISA entry of SARS-CoV-2 first dose generate healthcare worker highest IgA IgG immune response Immunity increase induce magnitude Medicine mRNA BNT162b2 much higher mucosal neutralizing antibody protocol Quantitative recipient Saliva Sample SARS-CoV-2 second dose seronegative seropositive individual seropositive individuals seropositive subjects serum serum IgG significantly single dose subjects supported surgery systemic immune response titre total antibody Umberto university vaccination vaccine dose virus were measured
[DOI] 10.1016/j.ebiom.2021.103788 PMC 바로가기 [Article Type] Clinical Trial

Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults

면역 저하가 없는 성인에서 BNT162b2 2회 투여 후 3개월 후 항체 역가 감소

Observational Study

Published on 2022-01-012022-09-12
Journal: Clinical microbiology and infection : the official [Category] 임상, 진단,

[키워드] acute respiratory syndrome age Analysis anti-RBD Anti-RBD antibodies Anti-RBD antibody Antibody titre BNT162b2 collected conditions coronavirus COVID-19 Decline declined dose first dose hospital Humoral immunity immunoassay Immunocompromised immunogenicity interquartile range maintain male marker median mild SARS-CoV-2 infection Neutralizing activity of BNT162b2 participant Prospective Quantitative raise receiving Receptor binding domain required SARS-CoV-2 second dose serum serum sample short-lived the antibody response the S1 subunit the spike protein threshold titre vaccination Vaccine was used were excluded were measured
[DOI] 10.1016/j.cmi.2021.08.023 PMC 바로가기 [Article Type] Observational Study